A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
| Condition | Type 2 Diabetes |
|---|---|
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Status | Completed |
| Enrollment | 401 participants |
| Interventions | Orforglipron |
| Start date | Sep 28, 2023 |
| Completion date | Jun 5, 2025 |
| Results posted | Jun 30, 2026 |
Summary
The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication. This study includes 3 periods as follows: * screening and lead-in period: up to 4 weeks * treatment period: 52 weeks, including 20 weeks of dose escalation, and * safety follow-up period: 2 weeks.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
| 3 mg Orforglipron | 107 Participants |
|---|---|
| 12 mg Orforglipron | 114 Participants |
| 36 mg Orforglipron | 118 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
- Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Uric Acid Lowering Trial in Youth Onset T2D — University of Colorado, Denver
- Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1 — State University of New York at Buffalo
- Continuous Glucose Monitoring Following Hospital Discharge — Kathleen Dungan
- Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on I — University of Colorado, Denver